Clinical Data, Inc. Chairman and PGxHealth Senior Vice President to Present to the Society for Experimental Biology and Medicine.Clinical Data, Inc. Chairman Randal J. Kirk New River Pharmaceuticals was acquired in a deal worth approximately $2.6 billion, making Randal J. Kirk, New River Pharmaceutical's founder, chairman and chief executive officer approximately $1.46 billion. and PGxHealth Senior Vice President Meeta Patnaik, M.D., to Discuss Applications of Pharmacogenomics Pharmacogenomics is the branch of pharmacology which deals with the influence of genetic variation on drug response in patients by correlating gene expression or single-nucleotide polymorphisms with a drug's efficacy or toxicity. in Drug Development and Utilization NEWTON, Mass. -- Clinical Data, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CLDA CLDA California Lyme Disease Association ), a leader in the development of targeted therapeutics and predictive tests from its growing portfolio of proprietary genetic biomarkers, announced today that Chairman Randal J. Kirk and Meeta Patnaik, Senior Vice President of PGxHealth, will present at The Society of Experimental Biology and Medicine's symposium: Progress in Pharmacogenomics and Its Promise for Medicine from 3:15 p.m. to 5:15 p.m. Sunday, April 6, 2008 at the San Diego Convention Center The San Diego Convention Center is the main convention center for the city of San Diego, California. It is located in the Marina district of downtown San Diego near the Gaslamp Quarter, at 111 West Harbor Drive. , Ballroom 20A, at 111 West Harbor Drive Harbor Drive is the name of a street in Portland, Oregon, which was formerly a freeway that carried U.S. Route 99W along the western shore of the Willamette River in the downtown area. . Clinical Data's PGxHealth division focuses on the use of genetic biomarkers associated with drug response to guide physicians and patients to the drug or drug class that is most likely to be effective. The session will be co-chaired by Clinical Data, Inc. board member Burton E. Sobel of the University of Vermont. Mr. Kirk and Dr. Patnaik will participate on a panel addressing how pharmacogenomics is being and will be used to manage patient care by helping identify patients that will respond better, have less side effects Side effects Effects of a proposed project on other parts of the firm. and toxic effects, and exclude those at risk of adverse drug reactions adverse drug reaction, n a detrimental outcome from a drug. Two types of ADRs exist: Type 1 results from dosage mismatch and Type 2 from rare conditions often as a consequence of a small dose. See also risk or sensitive type. to specific therapies, among other topics. Mr. Kirk's presentation will be titled "Implications of Pharmacogenomics for Drug Development." Dr. Patnaik's presentation is titled "Applications of Pharmacogenomics In the Use of Psychotropic Drugs." Both Mr. Kirk and Dr. Patnaik will be speaking on pharmacogenomics and its capabilities in genetic biomarker identification and validation to develop and commercialize novel genetic tests leading to safer and more efficacious ef·fi·ca·cious adj. Producing or capable of producing a desired effect. See Synonyms at effective. [From Latin effic therapeutics. Dr. Patnaik will use specific examples in the areas of schizophrenia, bipolar disease, and epilepsy to illustrate the power of pharmacogenetic tests to identify patients at risk for potentially fatal adverse drug reactions. The panel presentations will be captured for publication in the Society's journal, Experimental Biology and Medicine. For more information about the conference please refer to www.sebm.org/announcements.htm. About Clinical Data, Inc. Clinical Data, Inc. is a global biotechnology company unlocking the potential of molecular discovery, From Targeted Science to Better Healthcare[TM]. Its PGxHealth[TM] division focuses on proprietary biomarker and pharmacogenetic test development as well as targeted therapeutics to help predict drug safety and efficacy, thereby reducing health care costs and improving clinical outcomes. Its Cogenics[TM] division provides genomics services to both research and regulated environments. Through these divisions, Clinical Data is leveraging advances in molecular discovery to provide tangible benefits for patients, doctors, scientists and health plans worldwide. Visit the company's website at www.clda.com for more information. About PGxHealth(TM) This division of Clinical Data, Inc. has extensive experience and capabilities in the development, clinical validation and delivery of genetic tests that assist providers in targeting efficacious and safe drugs for their patients. PGxHealth also leverages its capabilities and intellectual property to develop therapeutics which are targeted at patient subpopulations where drug response is enhanced. Through its know-how and resources, work conducted with some of the world's most prestigious genomics thought leaders and institutions, and use of innovative technologies, PGxHealth is focused on reducing treatment costs and improving clinical outcomes in those disease states and therapeutic classes beset with expensive, inefficient or suboptimal Suboptimal A solution is called suboptimal if a part of the solution has been optimized without regards to the overall objective. treatment options. It has branded its genetic tests based on these proprietary genetic markers as Therapeutic Diagnostics(TM). For more information about PGxHealth, please visit its website at www.pgxhealth.com. About the Society for Experimental Biology and Medicine Founded in 1903, the Society for Experimental Biology and Medicine (SEBM) is a not-for-profit scientific society formed to promote investigation in the biomedical sciences by encouraging and facilitating interchange of scientific information among disciplines. The principal means for achieving this purpose are the publication of a peer-reviewed journal peer-reviewed journal Refereed journal Academia A professional journal that only publishes articles subjected to a rigorous peer validity review process. Cf Throwaway journal. , Experimental Biology and Medicine, and support of regional and national meetings. The Society also fosters the career development of students and new investigators. SEBM has over 1,300 members worldwide; the majority of whom have their doctoral degrees and are actively engaged in various fields of biomedical research Biomedical research (or experimental medicine), in general simply known as medical research, is the basic research or applied research conducted to aid the body of knowledge in the field of medicine. . Membership dues include a subscription to EBM EBM Evidence-Based Medicine EBM Electronic Body Music EBM ecosystem-based management EBM Evidence Based Medical (statistics) EBM Environmentally Benign Manufacturing EBM Expressed Breast Milk EBM Executive Board Meeting (online and print). Visit the The Society for Experimental Biology and Medecine website at www.sebm.org for more information. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion